Skip to main content

Table 1 Description of the IME characteristics before and after neoadjuvant chemotherapy in the entire population (comparison with paired-test)

From: Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study

   Before chemo (n = 66)
N (%)
After chemo (n = 66)
N (%)
 
TILs (%) Median 10.0 10.0 p = 0.5598
(Range) (1.0:95.0) (1.0:70.0)
TILs 0–10% 36 (54.5%) 35 (53.0%) p = 0.8474
> 10% 30 (45.5%) 31 (47.0%)
TILs 0–30% 56 (84.8%) 58 (87.9%) p = 0.5930
> 30% 10 (15.2%) 8 (12.1%)
PD-L1 Negative (IC0) 31 (47.0%) 38 (57.6%) p = 0.1936
Positive (IC1/2/3) 35 (53.0%) 28 (42.4%)
TIM-3 (%) Median 0.0 1.5 p < 0.0001
(Range) (0.0:15.0) (0.0:20.0)
TIM-3 < 1% 45 (68.2%) 21 (31.8%) p < 0.0001
≥1% 21 (31.8%) 45 (68.2%)
TIM-3 0–4% 57 (86.4%) 44 (66.7%) p = 0.0093
≥5% 9 (13.6%) 22 (33.3%)
PD-L1 and TIM-3 Others 62 (93.9%) 54 (81.8%) p = 0.0209
PD-L1+/TIM-3+ 4 (6.1%) 12 (18.2%)
LAG-3 (%) Median 2.5 3.0 p = 0.0389
(Range) (0.0:37.0) (0.0:23.0)
LAG-3 0 15 (22.7%) 11 (16.7%) p = 0.3173
> 0 51 (77.3%) 55 (83.3%)
LAG-3 0–9 49 (74.2%) 58 (87.9%) p = 0.0126
≥10 17 (25.8%) 8 (12.1%)